THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Dr. Loes Hollestein

Dr. Loes Hollestein is a clinical epidemiologist with a biomedical background and is affiliated with the Department of Dermatology of the Erasmus MC University Medical Centre. Dr. Hollestein is an expert in analyses of linked routinely collected health care data. She uses these databases to build population-based datasets of which there is a worldwide lack of data and/or samples to study skin cancer progression. Her aim is to improve skin cancer care by improving risk stratification.  It is her vision that skin cancer staging can be improved by combining multiple disciplines: 1) epidemiology for population-based data, 2) biology for molecular features and 3) computer science to combine multiple features.

Globe Linkedin Orcid

Dr. Loes Hollestein

is supervising

DC 15

Why SPACE-MEL?

The Dutch Early-Stage Melanoma (D-ESMEL) study is a unique opportunity to identify and validate prognostic features for melanoma with spatial single cell -omics technologies following from the SPACE-MEL project on a population-based level

Publications

Zhou, C., A.L. Mooyaart, T. Kerkour, M.W.J. Louwman, M. Wakkee, Y. Li, Q.J.M. Voorham, A. Bruggink, T.E.C. Nijsten, and L.M. Hollestein, The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma. Eur J Epidemiol, 2025. 40(1): p. 27-42.

 

Kerkour, T., L. Hollestein, A. Nigg, S.A. Koppes, T. Nijsten, Y. Li, and A. Mooyaart, Automated assessment of skin histological tissue structures by artificial intelligence in cutaneous melanoma. Pathol Res Pract, 2025. 269: p. 155923

 

Ouwerkerk, T. Kerkour, C. Zhou, A. Mooyaart, R. Boers, J. Boers, J.Gribnau, M. Wakkee, Y.Li, L.M. Hollestein, Genome-wide Methylation Profiles of primary and matched Distant Metastasis: Insights from the Dutch Early-Stage Melanoma (D-ESMEL) Study, accepted for publication in Human Genomics 2025.

 

Hollestein, L*., C. Eggermont*, M. Louwman, K. Schreuder, M. Drissen, O. Steijlen, A. Mooyaart, A. Gijsbers-Bruggink, Q. Voorham, D. Grunhagen, H. Jalving, T. Nijsten, and M. Wakkee, Longitudinal data on advanced cutaneous squamous cell carcinoma from the Dutch Keratinocyte Cancer Collaborative (DKCC): a nationwide real-world database study.  Lancet Reg Health Eur. 2025 Oct 18:59:101501

 

Rentroia-Pacheco, B., S. Tokez, E.M. Bramer, Z.C. Venables, H.J.G. van de Werken, D. Bellomo, D. van Klaveren, A.L. Mooyaart, L.M. Hollestein, and M. Wakkee, Personalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model. EClinicalMedicine, 2023. 63: p. 102150.